Top Markets
Coin of the day
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

CRVS
शेयरों में रैंक #8729
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
शेयर मूल्य
$14.07
अंतिम समन्वयन: 2026-08-28
मार्केट कैप
$1.18B
बदलाव (1 दिन)
-4.41%
बदलाव (1 वर्ष)
145.13%
देश
US
व्यापार Corvus Pharmaceuticals, Inc. (CRVS)

श्रेणी

Corvus Pharmaceuticals, Inc. (CRVS) के लिए P/B अनुपात
2026 को P/B अनुपात TTM: 0
Corvus Pharmaceuticals, Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी का वर्तमान P/B अनुपात (TTM) 0 है। 2026 के अंत में, कंपनी का P/B अनुपात 0 था।
Corvus Pharmaceuticals, Inc. के लिए 2026 से 2026 तक P/B अनुपात का इतिहास
हर वर्ष के अंत में P/B अनुपात
वर्ष P/B अनुपात परिवर्तन
प्रदान की गई तारीखों के लिए पर्याप्त डेटा नहीं।
समान कंपनियों या प्रतिस्पर्धियों के लिए P/B अनुपात
कंपनी P/B अनुपात P/B अनुपात में अंतर देश
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH